Kiniksa's Rilonacept Receives the US FDA's Orphan Drug Designation to Treat Pericarditis
Shots:
- The US FDA has granted ODD for Kiniksa’s Rilonacept to treat pericarditis- which includes recurrent pericarditis. The company plans to submit sBLA in recurrent pericarditis to the US FDA in late 2020
- Earlier- the company has reported the results of P-III RHAPSODY study that met its all 1EPs & 2EPs showing that the therapy improved clinical outcomes associated with the unmet medical need in recurrent pericarditis
- Rilonacept (SC- qw) is a recombinant fusion protein that blocks IL-1α and IL-1β signaling and has received the US FDA’s BT designation in 2019. In 2017- Regeneron out-licensed rilonacept to Kiniksa for recurrent pericarditis under which Regeneron will receive equal profit on sales of the therapy- if approved in the US
Ref: Kiniksa | Image: Kiniksa
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com